Acute Myeloid Leukemia Market Report and Forecast 2025-2034

Acute Myeloid Leukemia Market Overview

Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow and primarily affects adults. The average age for diagnosis of the disease is 69 years. The rising incidence, particularly among older adults, is propelling a surge in the demand for advanced treatment regimens for the condition. The market growth is spurred by multiple factors, such as developments in immunotherapy, personalized medicine, and early diagnosis. During the forecast period, the market value is expected to increase due to investments by pharmaceutical companies in innovative therapies.

Acute Myeloid Leukemia Market Growth Drivers

Rising Prevalence of Acute Myeloid Leukemia Drives Market Growth

The acute myeloid leukemia (AML) prevalence rate has been increasing, with about 20,800 new cases and 11,220 deaths from acute myeloid leukemia predicted by the American Cancer Society in 2024. AML accounts for about 1 in 3 leukemias in adults, presenting with an average age of diagnosis of around 69 years. This increasing prevalence, especially among adults, calls for more effective therapeutics creating novel opportunities in the market while pharmaceutical companies continue developing innovative new therapies for effective management.

Acute Myeloid Leukemia Market Trends

Acute Myeloid Leukemia Market Segmentation

Acute Myeloid Leukemia Market Share

Market Segmentation Based on the Treatment Type Set to Witness Substantial Growth

Based on the treatment type, the market is segmented into chemotherapy (anti-metabolites, alkylating agents, anthracycline drugs, others), targeted therapy, immunotherapy, and others. Among these, immunotherapy is expected to lead the market, driven by immune checkpoint inhibitors like Ipilimumab (Yervoy) and Atezolizumab (Tecentriq), which are expected to enhance immuno-oncology positively in the forecast period. The growing advancements in molecular biology and the increasing demand for personalized medicine are anticipated to bolster market growth during the forecast period.

Acute Myeloid Leukemia Market by Region

Based on the region, the market report offers insights into the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. Among these, the United States is anticipated to lead the market, owing to the existence of major pharmaceutical firms and substantial healthcare expenditure. Robust research efforts and governmental backing for cancer studies are aiding the expansion of the regional market.

Leading Players in the Acute Myeloid Leukemia Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Bristol-Myers Squibb Company

Headquartered in New York and a leading player in the field of immuno-oncology research, Bristol-Myers Squibb develops numerous drug types, including Reblozyl (luspatercept) and Opdivo (nivolumab). Opdivo is a PD-1 inhibitor developed for activating immunity by binding to the PD-1 receptor, which allows the immune system to detect and destroy tumor cells.

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche Ltd. is a global leader in pharmaceutical and diagnostics based in Basel, Switz...

Pfizer Inc.

The company was founded in New York in 1849. The development of Bosulif (bosutinib), a tyrosine kina...

Novartis AG

Novartis AG is a global pharmaceutical company based in Basel, Switzerland. The focus of this compan...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include AbbVie Inc., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Agios Pharmaceuticals, Inc., Jazz Pharmaceuticals plc., and Amgen Inc., among others.

Key Questions Answered in the Acute Myeloid Leukemia Market

• What was the acute myeloid leukemia market value in 2024?
• What is the acute myeloid leukemia market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is the market segmentation based on the disease type?
• What is the market breakup based on the treatment type?
• What is the market segmentation based on the route of administration?
• What is the market breakup based on the end user?
• What are the major factors aiding the acute myeloid leukemia market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major acute myeloid leukemia market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the acute myeloid leukemia market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What are the current treatment options for myeloblastic leukemia in the market?
• What is the significance of alkylating agents in leukemia therapy?
• What are the benefits of parenteral administration in acute myeloid leukemia therapies?
• How do hospitals manage acute myeloid leukemia treatments compared to specialty centres?
• How does the acute myeloid leukemia treatment market differ across EU-4 countries and the UK?